| Changing perspective on immunization against influenza. | |
| | |
MedLine Citation:
|
PMID: 17276554 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Current vaccination strategies against influenza rely on decades old technology of strain selection and prolonged labor-intensive, embryonated chicken-egg based production methods. Although, containing both major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), the immunity engendered by these vaccines is dominated by the anti-HA response. Consequently, current vaccines are susceptible to failure resulting from significant antigenic drift or shift in the time elapsing from the selection of the vaccine candidate strain and wild-type virus exposure. Therefore, immunity may be of short duration. There must be a change in vaccine strategy to include immunization with both HA and NA to broaden the immune response against influenza. Inclusion of the more slowly evolving NA in a vaccine against influenza will reduce the vulnerability to antigenic changes in a potential emerging influenza virus. Alternative production technologies such as recombinant baculovirus and yeast should be explored to decrease vaccine production times. |
| | |
Authors:
|
Bert E Johansson; Ian C Brett |
Related Documents
:
|
7217974 - Post-influenzal encephalitis during the influenza a outbreak in 1979/1980. 2781544 - Acute cerebellar ataxia after influenza vaccination with recurrence and marked cerebell... 18501484 - Influenza immunization and subsequent diagnoses of group a streptococcus-illnesses amon... 11770504 - Influenza activity--united states, 2001-02 season. 21536454 - Neurovirulence tests of three 17d yellow fever vaccine strains. 16884834 - Expression of human immunodeficiency virus type 1 tat from a replication-deficient herp... |
Publication Detail:
|
Type: Journal Article; Review Date: 2007-01-19 |
Journal Detail:
|
Title: Vaccine Volume: 25 ISSN: 0264-410X ISO Abbreviation: Vaccine Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-04-02 Completed Date: 2007-07-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8406899 Medline TA: Vaccine Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 3062-5 Citation Subset: IM |
Affiliation:
|
Innovation Sciences, Armonk, NY 10504, USA. bertjoh@pol.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Viral / blood, immunology Antigens, Viral / genetics Hemagglutinin Glycoproteins, Influenza Virus / genetics, immunology* Humans Influenza Vaccines / administration & dosage*, immunology Influenza, Human / immunology, prevention & control*, virology Neuraminidase / genetics, immunology* Vaccines, Synthetic / administration & dosage*, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Viral; 0/Antigens, Viral; 0/Hemagglutinin Glycoproteins, Influenza Virus; 0/Influenza Vaccines; 0/Vaccines, Synthetic; EC 3.2.1.18/Neuraminidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Identifying the epitope-specific T cell response to virus infections.
Next Document: Dermal testing of vaccines for children at high risk of allergies.